Guest Editors
Dr. Silvia Nuzzo
Email: silvia.nuzzo@synlab.it
Affiliation: IRCCS SYNLAB SDN, Naples, 80143, Italy
Homepage:
Research Interests: aptamers, cancer, delivery, targeted therapy, early diagnosis
Dr. Lisa Agnello
Email: lisa.agnello@synlab.it
Affiliation: IRCCS SYNLAB SDN, Naples, 80143, Italy
Homepage:
Research Interests: aptamers, cancer, delivery, targeted therapy, early diagnosis
Summary
Aptamers are short synthetic single stranded nucleic acids able to bind tightly to a target molecule. Thanks to their low/none immunogenicity, ease of synthesis, and versatility to chemical modifications, aptamers represent an attractive alternative for diagnostic, therapeutic, and precision delivery applications.
This Special Issue in Oncology Research aims to highlight the most recent advancements in aptamer research, with particular emphasis on innovative selection methodologies—such as next-generation SELEX approaches, in vivo and in silico screening strategies, and microfluidic-assisted platforms—as well as on the development of aptamer-based tools for the targeted delivery of secondary molecules (drugs, RNA-based therapeutics, imaging probes, and nanocarriers). Special attention will be given to studies exploring how aptamer engineering can improve tissue specificity, cellular uptake, and therapeutic efficacy.
We warmly invite contributions that explore novel mechanistic insights, technical optimizations, or translational perspectives in the field of aptamers. By assembling cutting-edge research and expert reviews, this Special Issue aims to provide an updated and integrative overview of how aptamer technology is shaping the future of targeted medicine, demonstrating its applicability in a wide range of oncological settings, from early diagnosis to advanced-stage treatment.
Keywords
aptamer, drug delivery, theranostics, cancer diagnostic, tumor therapy
Login
Register
Submit a Paper
Propose a Special lssue